Lytix Biopharma AS
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
- Conditions
- Advanced Melanoma
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 20
- Registration Number
- NCT04796194
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Levine Cancer Institute - Atrium Health, Charlotte, North Carolina, United States
🇺🇸University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center, Pittsburgh, Pennsylvania, United States
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 6
- Registration Number
- NCT03725605
- Locations
- 🇩🇰
Herlev Hospital, Copenhagen, Denmark
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
- Conditions
- CancerMelanomaBreast CancerHead and Neck CancerLymphomaTriple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 80
- Registration Number
- NCT01986426
- Locations
- 🇧🇪
Jules Bordet Institute, Bruxelles, Belgium
🇧🇪Cliniques Universitaires St-Luc, Service d'oncologie médicale, Bruxelles, Belgium
🇫🇷Institut Curie, Paris, France
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
- Conditions
- Non-bullous Impetigo
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 210
- Registration Number
- NCT01803035
- Locations
- 🇩🇴
Dr. Robert Reid Cabral Children Hospital, Santo Domingo, Dominican Republic
🇩🇴Institute of Dermatology and and Skin Surgery Dr. Hubert Bogaert Diaz, Santo Domingo, Dominican Republic
A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Lytix Biopharma AS
- Target Recruit Count
- 12
- Registration Number
- NCT01223209
- Locations
- 🇳🇴
University Hospital North-Norway, Tromsø, Norway
- Prev
- 1
- 2
- Next
News
Verrica to Present VP-315 Immune Activation Data from Phase 2 Basal Cell Carcinoma Trial at SITC 2025
Verrica Pharmaceuticals will present new data on VP-315, its oncolytic peptide therapy for basal cell carcinoma, at the Society for Immunotherapy of Cancer 40th Annual Meeting in November 2025.
Verrica Pharmaceuticals Reports Record Growth in YCANTH® Dispensed Units for Molluscum Contagiosum Treatment
Verrica Pharmaceuticals achieved a milestone with over 10,000 YCANTH® dispensed applicator units in Q1 2025, representing a 16.7% sequential increase from the previous quarter.